Nymox Pharmaceutical (NYMX) Annual Balance Sheets

Annual · GAAP · USD millions
Access NYMX quarterly Balance Sheets →
A period-by-period view of the balance sheet from Nymox Pharmaceutical to Dec 31 2020 helps clarify how Dec 31 2024's financial structure has changed over time.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2024)
(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Assets
Cash & cash equivalent0.07
Security Deposit0.04
Cash & Short-term Investments0.00
Other Receivables0.03
Inventories0.00
Other Current Assets0.52
Total Current Assets0.65
Equipment/Property/Plant Net0.00
Other Assets, Noncurrent0.00
Current Prepaid Expenses0.02
Trade And Other Current Payables-
Other Current Financial Liabilities-
Total Assets0.65
Liabilities
Accounts Payable4.14
Other Liabilities, Current7.43
Total Current Liabilities7.43
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
LongTermOperatingLeaseLiability-
Total Liabilities7.43
Stockholders' Equity
Other Equity-6.78
Common Stockholder's Equity-6.78
Total Stockholder's Equity-6.78
Liabilities & Stockholder's Equity0.65
4 historic quarters locked

Sign in to unlock the full Nymox Pharmaceutical balance sheet history.

About Nymox Pharmaceutical Corp Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 20-F (Period: 20241231)
  • Filed with the SEC: June 3, 2025
  • Source: nymox_20f.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001640334-25-000972

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License